INS and Hypoglycemia: AfrezzaTM, a dry-powder, rapid-acting inhaled insulin, is FDA-approved, but causes hypoglycemia, throat irritation, cough, and bronchospasm in patients with asthma or chronic pulmonary disease, with low bioavailability (~24%) [99,100,101,102].